NASDAQ:OSMTOsmotica Pharmaceuticals Stock Price, Forecast & News

Osmotica Pharmaceuticals' stock was trading at $5.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OSMT shares have increased by 73.3% and is now trading at $8.77. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Osmotica Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Osmotica Pharmaceuticals.

Osmotica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Osmotica Pharmaceuticals.

Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) posted its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.07. The business had revenue of $48.65 million for the quarter, compared to analysts' expectations of $43.76 million. Osmotica Pharmaceuticals had a negative net margin of 115.34% and a negative return on equity of 6.22%. View Osmotica Pharmaceuticals' earnings history.

5 equities research analysts have issued 12-month target prices for Osmotica Pharmaceuticals' shares. Their forecasts range from $4.00 to $12.00. On average, they anticipate Osmotica Pharmaceuticals' share price to reach $9.40 in the next year. This suggests a possible upside of 7.2% from the stock's current price. View analysts' price targets for Osmotica Pharmaceuticals.

Media coverage about OSMT stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Osmotica Pharmaceuticals earned a media sentiment score of -1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Osmotica Pharmaceuticals.

Osmotica Pharmaceuticals saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 590,800 shares, a decline of 52.4% from the May 31st total of 1,240,000 shares. Based on an average daily volume of 218,100 shares, the days-to-cover ratio is presently 2.7 days. Currently, 5.5% of the company's shares are sold short. View Osmotica Pharmaceuticals' Current Options Chain.

Some companies that are related to Osmotica Pharmaceuticals include Esperion Therapeutics (ESPR), Heron Therapeutics (HRTX), Portola Pharmaceuticals (PTLA), Karyopharm Therapeutics (KPTI), Innoviva (INVA), Kiniksa Pharmaceuticals (KNSA), Arvinas (ARVN), Theravance Biopharma (TBPH), Akcea Therapeutics (AKCA), Tricida (TCDA), Rocket Pharmaceuticals (RCKT), Amneal Pharmaceuticals (AMRX), Supernus Pharmaceuticals (SUPN), Constellation Pharmaceuticals (CNST) and Odonate Therapeutics (ODT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Osmotica Pharmaceuticals investors own include AT&T (T), Canopy Growth (CGC), AbbVie (ABBV), Gilead Sciences (GILD), Micron Technology (MU), SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ) and Eli Lilly And Co (LLY).

(OSMT) raised $58 million in an initial public offering on Thursday, October 18th 2018. The company issued 8,300,000 shares at $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities served as the underwriters for the IPO.

Osmotica Pharmaceuticals trades on the NASDAQ under the ticker symbol "OSMT."

Osmotica Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.23%). View institutional ownership trends for Osmotica Pharmaceuticals.

OSMT stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC. View insider buying and selling activity for Osmotica Pharmaceuticals.

Shares of OSMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OSMT stock can currently be purchased for approximately $8.77.

Osmotica Pharmaceuticals has a market capitalization of $451.83 million and generates $240.03 million in revenue each year. The company earns $-270,900,000.00 in net income (profit) each year or $0.25 on an earnings per share basis. Osmotica Pharmaceuticals employs 466 workers across the globe.

The official website for Osmotica Pharmaceuticals is www.osmotica.com.

Osmotica Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-809-1300 or via email at [email protected]